News
For the 2025-2026 respiratory viral season, Moderna intends to have mResvia available for both FDA-approved patient populations.
A letter to the US public on the AMA website, signed by 75+ medical societies, stresses the vital importance of influenza, RSV, and COVID-19 vaccines.
Research shows RSV leads to high hospitalization rates in adults, emphasizing the importance of enhanced surveillance and ...
Researchers found that older adults who received AS01-adjuvanted shingles or RSV vaccines had a significantly lower risk of ...
The Health and Human Services Department under Kennedy took unprecedented steps to change how vaccines are evaluated, ...
The Department of Health and Human Services under Robert F. Kennedy Jr. has taken unprecedented steps to change how vaccines ...
Studies have found important benefits from the new RSV immunization and enhanced versions of the flu shot. Plus, the shingles ...
The Centers for Disease Control and Prevention's vaccine advisory committee is set to meet for the first time since Health ...
A federal vaccine advisory committee plans to review the childhood vaccination schedule and scrutinize vaccines that have ...
"First, they provide evidence of vaccine protection against RSV-associated hospitalization, of which an estimated 60,000 to 160,000 occur annually among U.S. adults aged 65 years and older.
Previously, the vaccine, mResvia, was licensed for people 60 and older. Next up: Will CDC vaccine experts’ recommendation for adults 50 to 59 be endorsed?
Some results have been hidden because they may be inaccessible to you
Show inaccessible results